Tepezza is a prescription the U.S. Food and Drug Administration approved to treat thyroid eye disease.
Although initial trials showed the effectiveness of the medication, additional studies found a link to hearing loss, tinnitus, and similar medical conditions.
You may qualify to file a Tepezza Lawsuit if you experienced hearing-related problems after taking Tepezza.
Contact TruLaw for an instant case evaluation immediately to see if you qualify for a Tepezza Hearing Loss Lawsuit in as little as 60 seconds!
You might be entitled to compensation from the manufacturer for the harm you’ve suffered and losses you’ve incurred.
A new Tepezza lawsuit, Mhamdi v. Horizon Therapeutics USA, Inc., was recently filed in MDL by a Florida woman who claims to have suffered severe injuries, including permanent hearing loss and tinnitus, due to Tepezza infusions.
The plaintiff, who was diagnosed with thyroid eye disease and/or Graves’ Disease, received these infusions from August 2020 to February 2023. The lawsuit alleges that neither the plaintiff nor her physicians were provided with any warnings or knowledge about the potential serious risks of permanent hearing loss or tinnitus associated with Tepezza.
August 15th, 2023:
In the past month, five additional hearing loss cases related to Tepezza have been moved into the recently established Tepezza class action MDL. This development has increased the total number of pending cases to 46 in an MDL that has been in existence for only three months.
July 2023 Updates:
July 1st, 2023:
Judge Durkin held the first class action MDL status conference on June 28th.
The meeting brought together all parties and their attorneys to allow the judge to outline his strategy for effectively managing the lawsuits.
Moreover, Judge Dirken clarified the process for selecting lawyers to serve on the plaintiffs’ steering or executive committee.
June 2023 Updates:
June 16th, 2023:
U.S. District Judge Thomas Durkin recently issued a case management order in the Tepezza hearing damage MDL, scheduling the first status conference for June 28.
The conference will address the allowance of consolidated complaints involving multiple plaintiffs, potential evidence preservation orders, and the appointment of Tepezza lawyers to leadership positions.
Although Judge Durkin stated the final appointment of attorneys won’t take place until after the conference, he assured a decision can be expected promptly afterward.
June 12th, 2023:
A group of Tepezza attorneys filed a motion suggesting a list of attorneys including three co-lead counsel, one liaison counsel, and an executive committee comprising eight individuals, to take on leadership roles in the MDL case.
May 2023 Updates:
May 8th, 2023:
The number of Tepezza hearing loss lawsuits being filed nationwide has significantly risen in the past six weeks.
Initially, there were only 18 pending cases across five federal districts when a motion for MDL consolidation was filed in March.
However, since then, seven additional Tepezza hearing loss lawsuits have been filed in federal courts across the country.
The Judicial Panel on Multidistrict Litigation (JPML) is scheduled to review the possibility of creating a new class action MDL at the end of this month.
May 11th, 2023:
Horizon Therapeutics, the manufacturer of Tepezza, has filed a motion opposing the consolidation of Tepezza cases into an MDL.
Horizon argues that an MDL is unnecessary due to the limited number of pending cases and optimistically suggests that future Tepezza lawsuits will be few.
The JPML is set to hold a hearing on May 25, 2023, to determine whether the Tepezza cases in federal courts should be consolidated into a class action MDL.
April 2023 Updates:
A new case study from Stanford University found that hearing loss is linked to dosage levels of Tepezza injections.
The study focused on a 64-year-old woman who experienced hearing loss in both ears after a full round of Tepezza injections.
However, when she was taken off the injections, her hearing problems went away.
When she tried a lower dose a year later, she did not experience the same hearing loss.
This case study strengthens the evidence of a direct connection between Tepezza and hearing loss.
March 2023 Updates:
There have been four new lawsuits filed alleging the permanent hearing damage caused by Tepezza injections.
Out of the 34 cases filed in federal courts, there have been 13 voluntary dismissals.
These dismissals indicate that there may have been settlements.
February 2023 Updates:
February 14th, 2023:
Horizon Therapeutics filed a motion to dismiss the Tepezza hearing loss claims against it under the doctrine of federal preemption, arguing that the tort claims asserted by the Tepezza plaintiffs are preempted by federal law because the FDA regulated Horizon’s ability to change the warning label for Tepezza.
February 16th, 2023:
Nine Tepezza product liability lawsuits have been filed in federal courts, with the most recent being Diaz v. Horizon Therapeutics USA Inc. filed on February 14, 2023.
The plaintiff suffered permanent hearing loss and tinnitus after receiving Tepezza infusions and the complaint alleges that Horizon was aware of the drug’s potential for hearing loss.
January 2023 Updates:
A motion to consolidate Tepezza Lawsuits into multidistrict litigation (MDL) has been filed on behalf of ten individuals who have suffered from hearing loss after taking Tepezza.
Attorneys representing the claimants have requested that all Tepezza Hearing Loss claims be consolidated before one judge in the U.S. District Court for the Northern District of Illinois.
Tepezza lawsuits allege that Horizon Therapeutics knew or should have known about the risk of hearing loss from Tepezza, but failed to fully test the treatment and provide adequate warnings to users and the medical community.
Horizon has objected to the consolidation request, stating that the cases involve different facts and defenses that would not benefit from coordinated pretrial proceedings.
The number of Tepezza hearing loss lawsuits is expected to grow in the coming months as more patients discover that their hearing damage was caused by the drug.
Contact us for a free consultation, or use the chatbot on this page to see if you qualify for a Tepezza Lawsuit instantly.
How Tepezza Works
Tepezza is the brand name for teprotumumab-trbw.
It’s a prescription medication for treating thyroid eye disease (TED).
TED damages tissue around the eye and causes symptoms similar to Graves’ disease, an autoimmune disorder.
Progressive swelling, inflammation, and tissue changes lead to various symptoms, including pain, double vision, and watery eyes.
The drug doesn’t only manage TED symptoms.
It treats the disease at the source by blocking autoantibodies responsible for activating essential receptors affecting the eyes.
It helps to decrease inflammation, prevent tissue expansion behind the eye, and prevent muscle and fat tissue remodeling.
Initial studies showed significant improvement in double vision, proptosis, quality of life, and soft tissue inflammation in patients with moderate to severe TED.
However, an Endocrine Society study conducted in March 2021 found a risk of hearing loss as high as 65 percent.
During the study, 26 patients received Tepezza four times a day.
After taking the drug, the primary symptoms experienced include:
Subjective hearing loss – 23 percent of patients
Ringing in the ears – 27 percent of patients
A feeling of plugged ears – 12 percent of patients
Hearing their own voice more loudly than normal – 29 percent of patients
Of the participants in the study, three developed patulous eustachian tube dysfunction, a disorder causing the eustachian tube valve to stay open, distorting the sound of a person’s voice.
If you suffer from tinnitus, hearing loss, or another adverse effect of Tepezza, find out if you have a case by filling out our Instant Case Evaluation Form right now.
Our goal will be to help you get the compensation you need so you can focus on your recovery.
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.
Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.
Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.